Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680543 | 0.93 | USP2 (0.40) | USP2SMN1; SMN2CTSKNR1H2MEN1 | |
| SCHEMBL3255385 | 0.92 | CTSK (0.49) | USP2SMN1; SMN2CTSKNR1H2MEN1 | |
| SCHEMBL13785599 | 0.88 | NR1H2 (0.42) | USP2SMN1; SMN2CTSKNR1H2MEN1 | |
| SCHEMBL15188491 | 0.82 | CTSK (0.44) | USP2SMN1; SMN2CTSKNR1H2MEN1 | |
| SCHEMBL7378278 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL25422301 | 0.77 | USP2 (0.47) | USP2SMN1; SMN2NR1H2MEN1KMT2A | |
| SCHEMBL2540069 | 0.76 | MAPT (0.46) | USP2SMN1; SMN2CTSKNR1H2KMT2A | |
| SCHEMBL29022649 | 0.76 | MAPK1 (0.43) | USP2SMN1; SMN2CTSK | |
| SCHEMBL2525193 | 0.76 | MAPT (0.46) | USP2SMN1; SMN2CTSKNR1H2KMT2A | |
| SCHEMBL6221680 | 0.76 | NR1H2 (0.41) | USP2SMN1; SMN2CTSKNR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227464-A1 | DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE | Imperial Innovations Limited (GB) | 2010-09-15 | — | — | EP | claimed |
| WO-2009071906-A1 | DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-06-11 | — | — | WO | claimed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| EP-2227464-A1 | DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE | Imperial Innovations Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
| US-5952381-A | SELECTIVELY INHIBITING OR ANTAGONIZING THE INTEGRINS; ANTITUMOR AGENTS, ANTIARTHRITIC AGENTS, VIRICIDES, MICROBIOCIDES; TREATING OSTEOPOROSIS, SKIN DISORDERS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0894084-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0889877-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5852210-A | Cinnamic acid derivatives | G. D. SEARLE & CO. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5773646-A | INTEGRIN INHIBITORS | G. D. SEARLE & CO. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036862-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036860-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | USP2 453/4885SMN1; SMN2 2068/4885CTSK 2144/4885 |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | ADRB2, ADRA2A, ADRA2C | USP2 2367/4885SMN1; SMN2 1932/4885CTSK 2757/4885 |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | ADRB2, ADRA2A, ADRA2C | USP2 1654/4885SMN1; SMN2 3317/4885CTSK 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.